DOCSLIB.ORG

Outline Renal Mass

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Outline Renal Mass Contemporary Outline Management of Renal • Epidemiology Masses • Differential Diagnosis • Evaluation • Imaging Geoffrey N. Box, MD • Role for Biopsy Vice Chair of Educational Affairs Assistant Professor • Treatment Direct, Laparoscopic Urologic Surgery • Surveillance Department of Urology • Surgery The Ohio State University Wexner Medical Center • Ablation James Cancer Hospital and Solove Research Institute • Follow-up • Cases Renal Mass • Increasing incidence with widespread use of cross-sectional imaging • Renal lesions are seen in 15-25% of abdominal imaging studies ‒ Most are benign cysts • Majority are detected incidentally. ● = <2 cm, ▲ = 2 – 4 cm, ○ = >4 – 7 cm, and ∆ = >7 cm 1 Renal Mass- Differential Diagnosis Renal Mass- Differential Diagnosis Malignant Benign Inflammatory Renal Cell Carcinoma Simple cyst Abscess -Clear Cell Angiomyolipoma Focal pyelonephritis Malignant Benign -Papillary Oncocytoma Xanthogranulomatous -Chromophobe Metanephric adenoma pyelonephritis Renal Cell Carcinoma Simple cyst -Collecting duct Cystic Nephroma Tuberculosis -Clear Cell Angiomyolipoma Urothelial Based Mixed epithelial/stromal -Urothelial tumor -Papillary Oncocytoma carcinoma Reninoma -Chromophobe -Squamous cell Leimyoma -Adenocarcinoma Pseudotumor Sarcoma Wilms tumor Carcinoid Lymphoma Leukemia Metastasis Is it Benign or Radiographic Assessment Malignant? • Ultrasound • The question at hand. • CT • This can frequently determined by • MRI radiographic assessment. • Size Matters • Key Point: • Current trend is to biopsy more renal masses ‒ Need to determine enhancement <4cm. 2 Ultrasound CT Scan • Triple Phase (Renal Protocol) • Reliable for ‒ Pre-contrast differentiation of ‒ Post-contrast (venous phase) a solid lesion Cyst ‒ Delayed (10 min) Tissue HU from fluid. Bone +1000 Blood 40 • Can establish Kidney 30 the diagnosis of Water 0 a simple cyst. • Hounsfield Units (HU) Fat -50 Solid Mass ‒ Represents the density of Air -1000 tissue Enhancement CT-Enhancement • Can only be determined if a contrast agent is used ‒ CT – iodonated contrast • Enhancing Lesion = Pre-contrast to Post-contrast change in HU >15-20 ‒ MRI – Gadolinium Pre-contrast HU: 15 • Slightly more subjective Post-contrast HU: 55 3 MRI Risk of Contrast Agents • Pre and Post Gadolinium • IV Contrast (CT) ‒ Contrast Allergy ‒ Nephrotoxicity • Avoid with severe renal impairment • Risk reduction: Hydration • Gadolinium (MRI) ‒ No nephrotoxicity ‒ Risk of Nephrogenic Systemic Fibrosis in those with severe renal impairment (EGFR<30). cG250 PET/CT: Radiolabeled Antibody Fat • 124I-cG250 • Solid masses with areas (REDECTANE®) of negative HU (<-20) ‒ Binds carbonic indicate the presence of anhydrase IX fat and are diagnostic of ‒ Clear cell RCC AMLs. ‒ Radiographic diagnosis • AML = Angiomyolipoma • No role for CT PET- • AML is a benign tumor. FDG with renal 18F-FDG tumors. 124I-cG250 Wilex AG, Munich, Germany 4 Renal Cysts: Bosniak Renal Cysts Classification Bosniak Class Description Cancer Risk Management • The kidney is one of the most common locations in the body for cyst formation. No enhancement Smooth Wall I No Septa 0% None • Renal cysts are cavities derived from renal tubules. No Calcifications No enhancement • Composed of a layer of epithelial II Hairline Septa Minimal None cells enclosing a cavity filled with Fine Calcifications urine-like liquid or semi-solid No enhancement material. Hyperdense lesion IIF Multiple Septa <10% Surveillance Thicker Calcifications • 20% by age 40 Thickened Wall with • 50% by age 60 III Enhancement 50% Surgery IV Enhancing Nodule 90% Surgery Adapted from Campbell-Walsh Urology 10th Ed. Renal Cysts – Bosniak Classification Case- Simple Renal Cyst I II • Pictures of each III IV 5 Imaging Interpretation Role for Biopsy • Enhancing renal masses are most likely malignant. • Historically, renal masses have not been biopsied. • Simple Cysts (Bosniak Type I): ‒ Most are malignant ‒ Can be diagnosed by U/S or CT. ‒ Do not need follow-up. ‒ Issues with accuracy/non-diagnostic rates • AMLs are benign and can be followed ‒ Fear of needle tract seeding ‒ >4cm = greater risk for spontaneous ‒ High reported complication rates bleeding • Selective angioembolization vs. surgery AML = Angiomyolipoma Role for Biopsy Role for Biopsy • Contemporary results of renal mass • Current role for biopsy is expanding biopsy: ‒ Especially for masses <4cm ‒ Diagnostic rate: 92%. • RCC Subtype Concordance: 80-100% • Updated date on biopsy results are much • Fuhrman Grade Concordance: 50-70% improved. ‒ Complications: <5% • Hematoma most common Marconi et al. Eur Urol 2015 6 Indications: Indications: Renal Mass Biopsy Renal Mass Biopsy • R/o non-renal primary (mets or lymphoma) • R/o non-renal primary (mets or lymphoma) • +/- R/o benign lesions • +/- R/o benign lesions • Confirm diagnosis and histologic subtype in • Confirm diagnosis and histologic subtype in patients with metastases or unresectable patients with metastases or unresectable lesions lesions • Confirm diagnosis: • Confirm diagnosis: ‒ Prior to ablative therapy ‒ Prior to ablative therapy ‒ In patients considering observation when ‒ In patients considering observation when surgery is high risk surgery is high risk Indications: Renal Mass Biopsy Tumor Size and Pathology • R/o non-renal primary (mets or lymphoma) Tumor Size RCC Benign* High Grade • +/- R/o benign lesions ≤2.0 75% 25% 4% Biopsy only if it will change management • Confirm diagnosis and histologic subtype in 2.1-3.0 80% 20% 5% patients with metastases or unresectable lesions 3.1-4.0 84% 16% 25% • Confirm diagnosis: ‒ Prior to ablative therapy *Oncocytoma and AML – 75% ‒ In patients considering observation when surgery is high risk J Urol 2006; 176:896 7 Renal Cancer 2015 Renal Cell Carcinoma – • Incidence Risk Factors ‒ 61,560 new cases • Tobacco Exposure ‒ 14,080 deaths ‒ May account for ~20% of cases • Obesity • Peak incidence 5th-7th decades ‒ May account for ~40% of cases in US ‒ Risk increases ~30% for every 5kg/m2 increase in BMI • Men > Women • Hypertension • Lifetime Probability of Developing Renal Cancer: • Low socioeconomic status and urban background ►1 in 49 male (#7) • More than 100 chemicals have been investigated ►1 in 84 female (#10) but none have been definitively established as American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015 causative in RCC Renal Cancer – Mortality Renal Cancer – Presentation and Survival Site Incidence/yr Deaths 2015 Stage at Prostate Cancer 220,800 27,540 (12%) Diagnosis Distribution 5-yr Survival Localized 61% 91% Bladder Cancer 74,000 16,000 (22%) Regional 17% 63% Kidney Cancer 61,560 14,080 (23%) (lymph nodes) Distant 18% 11% (metastatic) American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015 Seer Database 8 Clinical Presentation Paraneoplastic syndromes • 80% incidental • “Internist’s Tumor” • Elevated ESR 55% • HTN 38% • Flank pain • Anemia 36% • Gross hematuria • Cachexia 35% “Classic Triad” <10% • Pyrexia 17% • Palpable mass • Elevated LFTs 14% • Microhematuria • Hypercalcemia 5% • Polycythemia 4% • Paraneoplastic syndromes (10-20%) • Neuromyopathy 3% Campbell-Walsh Urology 10th Ed. Clinical Presentation - RCC Renal Cell Carcinoma: Histologic Subtypes • Local Tumor Growth ‒ Hematuria ‒ Flank Pain ‒ Abdominal Mass • Metastasis ‒ Persistent Cough ‒ Bone Pain ‒ Cervical Lymphadenopathy ‒ Constitutional Symptoms Type: Clear cell Papillary Chromophobe Oncocytoma • Obstruction of IVC ‒ Bilateral Lower Extremity Edema Freq (%): 75 15 5 5 ‒ Right-sided Varicocele (or nonreducing Varicocele) 9 Hereditary RCC VHL: Renal Cell Carcinoma Gene • RCC occurs in 50% of VHL Disease (chromosome) Histology Frequency patients von Hippel-Lindau VHL (3) Clear Cell 75% ‒ Males=females in VHL ‒ 4th to 5th decade (39) HLRCC* FH (1) Papillary Type 2 10% ‒ Now most common cause of death Multiple Renal Cysts Chromophobe/Onc Containing RCC Birt-Hogg-Dube BHD (17) 10% ocytoma Hereditary Met (7) Papillary Type 1 5% papillary RCC *HLRCC = Hereditary Leiomyomatosis Renal Cell Carcinoma Sporadic Inherited Clear Cell RCC Renal Cell Carcinoma: Treatment Options Staging • Surveillance Stage Tumor Lymph Nodes Metastasis • Surgical Excision I T1 (<7cm) N0 M0 Gold Standard ‒ Radical Nephrectomy ‒ Partial Nephrectomy II T2 (>7cm) N0 M0 T1 or T2 N1 • Needle Ablation III M0 T3 (vein/fat) N0 or N1 ‒ Cryoablation or Radiofrequency Ablation T4 (outside Any N Any M IV Gerota’s) Any N M1 • RCC does NOT respond to chemotherapy or Any T radiation 10 Decision Making Active Surveillance (AS) • Tumor Characteristics: • Incidentally detected tumors: ‒ Size ‒ Small size (<4cm) ‒ Location ‒ Elderly ‒ Appearance ‒ Patients with significant comorbidity unfit for surgery • Patient Characteristics ‒ Comorbid disease ‒ Life expectancy • Opportunity to observe the natural history ‒ Patient desire of these small tumors. Tumor Size and Pathology Active Surveillance • Tumors <3cm Tumor Size RCC Benign* High Grade ‒ Risk of developing metastasis in 3 ≤2.0 75% 25% 4% years is ~1% • Average growth rate ~0.3cm/yr 2.1-3.0 80% 20% 5% • Most studies only have limited follow-up 3.1-4.0 84% 16% 25% • Follow-up protocol is not defined *Oncocytoma and AML – 75% ‒ Repeat imaging every 6-12 months J Urol 2006; 176:896 11 Active Surveillance Risk-adapted Management • Biopsy can be helpful • AUA Guidelines: ‒ “AS is a reasonable option for • More favorable histology: patients with a limited life ‒ Papillary type 1 expectancy or for those who are ‒ Chromophobe unfit for or do not desire intervention.”
Load more

Recommended publications
  • Non-Wilms Renal Cell Tumors in Children
    PEDIATRIC UROLOGIC ONCOLOGY 0094-0143/00 $15.00 + .OO NON-WILMS’ RENAL TUMORS IN CHILDREN Bruce Broecker, MD Renal tumors other than Wilms’ tumor are tastases occur in 40% to 60% of patients with infrequent in childhood. Wilms’ tumors ac- clear cell sarcoma of the kidney, whereas they count for 6% to 7% of childhood cancer, are found in less than 2% of patients with whereas the remaining renal tumors account Wilms’ tumor.**,26 This distinct clinical behav- for less than l%.27The most common non- ior is one of the features that has led to its Wilms‘ tumors are clear cell sarcoma of the designation as a separate tumor. Other clini- kidney, rhabdoid tumor of the kidney (both cal features include a lack of association with formerly considered unfavorable Wilms’ tu- sporadic aniridia or hemihypertrophy. mor variants but now considered separate tu- Clear cell sarcoma of the kidney has not mors), renal cell carcinoma, mesoblastic been reported to occur bilaterally and is not nephroma, and multilocular cystic nephroma. associated with nephroblastomatosis. It has Collectively, these tumors account for less been reported in infancy and adulthood, but than 10% of the primary renal neoplasms in the peak incidence is between 3 and 5 years childhood. of age. It has an aggressive behavior that responds poorly to treatment with vincristine and actinomycin alone, leading to its original CLEAR CELL SARCOMA designation by Beckwith as an unfavorable histology pattern. The addition of doxorubi- Clear cell sarcoma of the kidney is cur- cin in aggressive chemotherapy regimens has rently considered a separate tumor distinct improved outcome.
    [Show full text]
  • Pediatric Abdominal Masses
    Pediatric Abdominal Masses Andrew Phelps MD Assistant Professor of Pediatric Radiology UCSF Benioff Children's Hospital No Disclosures Take Home Message All you need to remember are the 5 common masses that shouldn’t go to pathology: 1. Infection 2. Adrenal hemorrhage 3. Renal angiomyolipoma 4. Ovarian torsion 5. Liver hemangioma Keys to (Differential) Diagnosis 1. Location? 2. Age? 3. Cystic? OUTLINE 1. Kidney 2. Adrenal 3. Pelvis 4. Liver OUTLINE 1. Kidney 2. Adrenal 3. Pelvis 4. Liver Renal Tumor Mimic – Any Age Infection (Pyelonephritis) Don’t send to pathology! Renal Tumor Mimic – Any Age Abscess Don’t send to pathology! Peds Renal Tumors Infant: 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Child: 1) Wilm's tumor 2) lymphoma 3) angiomyolipoma 4) clear cell sarcoma 5) multilocular cystic nephroma Teen: 1) renal cell carcinoma 2) renal medullary carcinoma Peds Renal Tumors Infant: 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Child: 1) Wilm's tumor 2) lymphoma 3) angiomyolipoma 4) clear cell sarcoma 5) multilocular cystic nephroma Teen: 1) renal cell carcinoma 2) renal medullary carcinoma Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor - Most common - Can’t distinguish from congenital Wilms. Renal Tumors - Infant 1) mesoblastic nephroma 2) nephroblastomatosis 3) rhabdoid tumor Look for Multiple biggest or diffuse and masses. ugliest. Renal Tumors - Infant 1) mesoblastic
    [Show full text]
  • The Largest Cystic Nephroma Treated by Laparoscopic Nephron
    CASE REPORT Urooncology Doi: 10.4274/jus.galenos.2018.2190 Journal of Urological Surgery, 2019;6(2):148-151 The Largest Cystic Nephroma Treated by Laparoscopic Nephron- sparing Surgery: A Case Report and Review of the Literature Laparoskopik Nefron Koruyucu Cerrahi ile Tedavi Edilen En Büyük Kistik Nefroma Olgusu: Olgu Sunumu Eşliğinde Literatürün Gözden Geçirilmesi Nejdet Karşıyakalı1, Uğur Yücetaş1, Hüseyin Aytaç Ateş4, Sevim Baykal Koca2, Ceyda Turan Bektaş3, Mahmut Gökhan Toktaş1 1İstanbul Training and Research Hospital, Clinic of Urology, İstanbul, Turkiye 2İstanbul Training and Research Hospital, Clinic of Pathology, İstanbul, Turkiye 3İstanbul Training and Research Hospital, Clinic of Radiology, İstanbul, Turkiye 4Siirt State Hospital, Clinic of Urology, Siirt, Turkiye Abstract Cystic nephroma is a rare benign tumour of the kidney. The symptoms are often non-specific and the diagnosis of the disease is usually made incidentally. Definitive diagnosis can be possible with histopathological evaluation. Surgical resection provides curative treatment. We report a successful removal of cystic nephroma in a 67-year-old female which was managed by laparoscopic nephron-sparing surgery. When a renal mass including multiple cystic formations is visualized on radiological imaging, the clinician should consider cystic nephroma for differential diagnosis, and these cases should be evaluated in terms of nephron-sparing surgery. Keywords: Cystic nephroma, Laparoscopy, Partial nephrectomy, Renal cyst, Renal tumour Öz Kistik nefroma böbreğin nadir görülen iyi huylu bir tümörüdür. Semptomlar sıklıkla özellikli değildir ve tanı genellikle rastlantısal olarak konulmaktadır. Kesin tanı histopatolojik değerlendirme sonrasında mümkündür. Cerrahi rezeksiyon küratif tedavi yaklaşımı sağlar. Laparoskopik nefron koruyucu cerrahi ile başarılı bir şekilde tedavi ettiğimiz 67 yaşındaki kadın hastada kistik nefroma olgusunu sunduk.
    [Show full text]
  • Mixed Epithelial and Stromal Tumor of the Kidney and Cystic Nephroma Share Overlapping Features Reappraisal of 15 Lesions
    Mixed Epithelial and Stromal Tumor of the Kidney and Cystic Nephroma Share Overlapping Features Reappraisal of 15 Lesions Tatjana Antic, MD; Kent T. Perry, MD; Kathleen Harrison, PhD; Polina Zaytsev, MD; Michael Pins, MD; Steven C. Campbell, MD, PhD; Maria M. Picken, MD, PhD c Context.ÐCystic nephroma is a rare cystic tumor, which and smooth muscle differentiation was con®rmed by elec- only recently has been recognized as an exclusively adult tron microscopy. In mixed epithelial and stromal tumors of lesion. Mixed epithelial and stromal tumor of the kidney is the kidney, the stroma was positive for estrogen and pro- also a rare, recently recognized, biphasic tumor composed gesterone receptors in 4 of 5 lesions tested. In cystic ne- of tubular and cystic elements embedded in grossly rec- phroma, focal positivity for hormone receptors was seen ognizable spindle cell stroma. The histogenesis of both le- in 2 of 7 tumors tested; both positive lesions were from sions is unclear. women. The epithelial lining in both mixed epithelial and Objectives.ÐTo compare clinical phenotype, morphol- stromal tumor of the kidney and cystic nephroma lesions ogy, and immunohistochemistry in mixed epithelial and was variable with regard to shape, cytoplasmic appear- stromal tumor of the kidney and cystic nephroma in order ance, and immunophenotype (with focal positivity for to explore the relationship between these 2 lesions. CD10, cytokeratin 7, high-molecular-weight keratin, and Design.ÐFifteen biphasic lesions (8 mixed epithelial and Ulex europaeus detectable in both lesions). This pattern stromal tumors of the kidney and 7 cystic nephromas) were suggests variable differentiation, which was con®rmed by studied.
    [Show full text]
  • Histological Typing of Kidney Tumours
    INTERNATIONAL HISTOLOGICAL CLASSIFICATION OF TUMOURS No.25 Histological Typing of Kidney Tumours WORLD HEALTH ORGANIZATION ISBN 9241760257 ©World Health Organization 1981 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or in toto, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. Authors alone are responsible for views expressed in this publication. PRINTED IN THE UNITED STATES OF AMERICA 79/4368-Waverly-5750 INTERNATIONAL HISTOLOGICAL CLASSIFICATION OF TUMOURS No. 25 HISTOLOGICAL TYPING OF KIDNEY TUMOURS F. K. MOSTOFI Head, WHO Collaborating Centre for the Histological
    [Show full text]
  • Anaplastic Sarcoma of the Kidney: Case Report and Literature Review Chien‑Chin Chena,B, Kai‑Sheng Liaoa,C*
    [Downloaded free from http://www.tcmjmed.com on Friday, May 31, 2019, IP: 118.163.42.220] Tzu Chi Medical Journal 2019; 31(2): 129–132 Case Report Anaplastic sarcoma of the kidney: Case report and literature review Chien-Chin Chena,b, Kai-Sheng Liaoa,c* aDepartment of Pathology, Ditmanson Medical Foundation, Abstract Chiayi Christian Hospital, We present a case of a 22-year-old female with gross hematuria for 1 month. A 9.5-cm Chiayi, Taiwan, bDepartment tumor was found at her left kidney. On suspicion of a renal cancer, she received left of Cosmetic Science, Chia nephrectomy. Histologically, it was a hypercellular tumor with undifferentiated anaplastic Nan University of Pharmacy neoplastic cells in fascicular sheets intermixed with chondroid nodules. The differential and Science, Tainan, Taiwan, cDepartment of Nursing, diagnoses included anaplastic sarcoma of the kidney (ASK), anaplastic Wilms tumor, Chung-Jen College of mesenchymal chondrosarcoma, sarcomatoid renal cell carcinoma, clear cell sarcoma Nursing, Health Sciences and of the kidney, rhabdoid tumor of the kidney, congenital mesoblastic nephroma, and Management, Chiayi, Taiwan synovial sarcoma. Based on the results of the work-up and literature review, ASK was diagnosed. The postoperative recovery was uneventful, and the patient began adjuvant chemotherapy (Ifosfamide [1800 mg/m2] and Epirubicin [60 mg/m2]) 5 weeks after the operation. Herein, we present this case to share the experience on an extremely rare entity. Received : 01-Aug-2018 Keywords: Anaplastic sarcoma, Mesenchymal chondrosarcoma, Renal tumor, Revised : 03-Sep-2018 Accepted : 02-Oct-2018 Sarcomatoid carcinoma, Wilms tumor Introduction hemorrhage with a large hematoma. After cutting, there was naplastic sarcoma of the kidney (ASK) is one of the rarest one 9.5 cm × 7 cm × 4.5 cm tumorous mass at the lower pole renal tumors.
    [Show full text]
  • Benign Renal Tumours Extremely Common – Esp. in Females
    Benign renal tumours Benign renal tumours Extremely common – esp. in females < 45 yrs May arise from cortical tissue (adenoma/oncocytoma) or differing mesenchymal elements Types: Benign renal cyst Renal cortical adenoma Metanephric adenoma Oncocytoma Angiomyolipoma Cystic nephroma Mixed epithelial stromal tumour of kidney (MESTK) Leiomyoma Others Fibroma Lipoma Lymphangioma Haemangioma Juxtaglomerular tumour (reninoma) Benign renal cyst Commonest renal lesion – accounts for 70% Male:female 2:1 Seen in 50% individuals over 50 yrs Growth rate 2.8mm/yr (Terada 2002) – faster in young pts Large symptomatic cysts may require Rx: percutaneous aspiration/sclerosis successful in 90% (Hanna 1996) using 95% alcohol. More recently laparoscopic decompression reportedly safe (Roberts 2001) Renal cortical adenoma Controversial diagnosis Small tumours arising from renal cortex well documented. Post-mortem studies indicate incidence of 7-23% [incidence on USS screening much lower @ <1%; Tosaka 1990]. Typically well-circumscribed lesions with uniform cells and unremarkable nuclear features, usually arranged in tubulopapillary or papillary arrays. Bell reported low rate of metastasis (~5%) of such lesions when <3cm when compared with a rate of 66% for lesions >3cm (Bell 1938, 1950). Led to pervasive 3cm rule. However now generally believed that all solid epithelium-derived tumours potentially malignant. Reasons: Increase with age Male:female ratio 3:1 Associated with smoking More common in VHL disease and acquired renal cystic disease Commonly exhibit
    [Show full text]
  • Kidney Solid Tumor Rules
    Kidney Equivalent Terms and Definitions C649 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: Tables and rules refer to ICD-O rather than ICD-O-3. The version is not specified to allow for updates. Use the currently approved version of ICD-O. Note 2: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 3: Renal cell carcinoma (RCC) 8312 is a group term for glandular (adeno) carcinoma of the kidney. Approximately 85% of all malignancies of the kidney C649 are RCC or subtypes/variants of RCC. • See Table 1 for renal cell carcinoma subtypes/variants. • Clear cell renal cell carcinoma (ccRCC) 8310 is the most common subtype/variant of RCC. Note 4: Transitional cell carcinoma rarely arises in the kidney C649. Transitional cell carcinoma of the upper urinary system usually arises in the renal pelvis C659. Only code a transitional cell carcinoma for kidney in the rare instance when pathology confirms the tumor originated in the kidney. Note 5: For those sites/histologies which have recognized biomarkers, the biomarkers are most frequently used to target treatment. Biomarkers may identify the histologic type. Currently, there are clinical trials being conducted to determine whether these biomarkers can be used to identify multiple primaries.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood Kris Ann P. Schultz1, Surya P. Rednam2, Junne Kamihara3, Leslie Doros4, Maria Isabel Achatz5, Jonathan D. Wasserman6, Lisa R. Diller7, Laurence Brugieres 8, Harriet Druker9,10, Katherine A. Schneider11, Rose B. McGee12, and William D. Foulkes13 Abstract PTEN hamartoma tumor syndrome (PHTS), DICER1 syn- ovarian sex cord–stromal tumors, and multinodular goiter and drome, and hereditary leiomyomatosis and renal cell cancer thyroid carcinoma as well as brain tumors including pineoblas- (HLRCC) syndrome are pleiotropic tumor predisposition syn- toma and pituitary blastoma. Individuals with HLRCC may dromes that include benign and malignant neoplasms affecting develop multiple cutaneous and uterine leiomyomas, and they adults and children. PHTS includes several disorders with shared have an elevated risk of renal cell carcinoma. For each of these and distinct clinical features. These are associated with elevated syndromes, a summary of the key syndromic features is provided, lifetime risk of breast, thyroid, endometrial, colorectal, and renal the underlying genetic events are discussed, and specific screening cancers as well as melanoma. Thyroid cancer represents the is recommended. Clin Cancer Res; 23(12); e76–e82. Ó2017 AACR. predominant cancer risk under age 20 years. DICER1 syndrome See all articles in the online-only CCR Pediatric Oncology includes risk for pleuropulmonary blastoma, cystic nephroma, Series. Introduction PHTS PTEN hamartoma tumor syndrome (PHTS), DICER1 syn- PHTS (OMIM þ601728) encompasses several autosomal drome, and hereditary leiomyomatosis and renal cell cancer dominant disorders with both overlapping and distinctive syndrome are pleiotropic tumor predisposition syndromes that features (1).
    [Show full text]
  • CT and MRI Findings of Angiomyolipoma with Epithelial
    J Korean Soc Radiol 2010 ; 63 : 173 - 176 CT and MRI Findings of Angiomyolipoma with Epithelial Cysts of the Kidney: A Case Report1 Dong-Myung Yeo, M.D., Dong Jin Chung, M.D., Tae-Jung Kim, M.D.2, In Kyu Lee, M.D.3, Seong Tai Hahn, M.D., Jae Mun Lee, M.D. Angiomyolipoma with epithelial cysts (AMLEC) or cystic angiomyolipoma has been recently described as a distinct cystic variant of angiomyolipoma. Although angiomy- olipoma (AML) is usually composed of adipose, vascular, and muscular tissue lacking an epithelial element, AMLEC contains an epithelial component in the form of gross or microscopic cysts. To date, the radiologic appearance of AMLEC has been demon- strated in only one case report, as a solid mass containing a tiny cystic focus. This re- port shows another imaging feature of AMLEC, which presents as a multiloculated cystic mass without a visible solid portion on CT and MRI. Index words : Kidney Diseases, Cystic Kidney Neoplasms Angiomyolipoma Angiomyolipoma (AML) is a mesenchymal neoplasm (3). In this report, we present a case of AMLEC in a 67- composed of variable proportions of dysmorphic blood year-old man presenting as a multilocular cystic mass vessels, smooth muscle, and adipose tissue. AMLs are without a visible solid portion and located in the kidney. typically solid lesions both radiologically and pathologi- cally (1). Recently, AMLs, including the gross or micro- Case Report scopic cystic component, have been reported in the pathologic literature and discovered as AML embedding A 67-year-old man presented with a right renal mass, epithelial elements in the form of cysts and termed AML which was incidentally detected during CT scan as part with epithelial cysts (AMLEC) or cystic AML (1, 2).
    [Show full text]
  • Multilocular Cystic Renal Cell Carcinoma Is a Subtype of Clear Cell Renal Cell Carcinoma
    Modern Pathology (2010) 23, 931–936 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 931 Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma Shams Halat1, John N Eble1, David J Grignon1, Antonio Lopez-Beltran3, Rodolfo Montironi4, Puay-Hoon Tan5, Mingsheng Wang1, Shaobo Zhang1, Gregory T MacLennan6 and Liang Cheng1,2 1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; 2Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA; 3Department of Pathology, Cordoba University, Cordoba, Spain; 4Institute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy; 5Department of Pathology, Singapore General Hospital, Singapore and 6Department of Pathology, Case Western Reserve University, Cleveland, OH, USA Multilocular cystic renal cell carcinoma is an uncommon low grade renal cell carcinoma with unique morphologic features. Its cytogenetic characteristics have not been fully investigated. Its relationship to typical clear cell renal cell carcinoma is uncertain. We evaluated 19 cases of multilocular cystic renal cell carcinoma diagnosed by strict morphologic criteria using the 2004 WHO classification system. The control group consisted of 19 low grade (Fuhrman grades 1 or 2) clear cell renal cell carcinomas. Chromosome 3p deletion status was determined by dual color interphase fluorescence in situ hybridization analysis. Chromosome 3p deletion was identified in 17 out of 19 (89%) of the clear cell renal cell carcinoma cases and 14 out of 19 (74%) of the multilocular cystic renal cell carcinoma cases, respectively. There was no difference in the status of chromosome 3p deletion between clear cell renal cell carcinoma and multilocular cystic renal cell carcinoma (P ¼ 0.40).
    [Show full text]
  • DICER1 Syndrome: DICER1 Mutations in Rare Cancers Jake C
    Boise State University ScholarWorks Biology Faculty Publications and Presentations Department of Biological Sciences 5-1-2018 DICER1 Syndrome: DICER1 Mutations in Rare Cancers Jake C. Robertson Boise State University Cheryl L. Jorcyk Boise State University Julia Thom Oxford Boise State University cancers Review DICER1 Syndrome: DICER1 Mutations in Rare Cancers Jake C. Robertson 1, Cheryl L. Jorcyk 1,2 ID and Julia Thom Oxford 1,2,* ID 1 Department of Biological Sciences, Boise State University, Boise, ID 83725-1515, USA; [email protected] (J.C.R.); [email protected] (C.L.J.) 2 Biomolecular Research Center, Boise State University, Boise, ID 83725-1511, USA * Correspondence: [email protected]; Tel.: +1-208-426-2395 Received: 9 April 2018; Accepted: 14 May 2018; Published: 15 May 2018 Abstract: DICER1 syndrome is a rare genetic disorder that predisposes individuals to multiple cancer types. Through mutations of the gene encoding the endoribonuclease, Dicer, DICER1 syndrome disrupts the biogenesis and processing of miRNAs with subsequent disruption in control of gene expression. Since the first description of DICER1 syndrome, case reports have documented novel germline mutations of the DICER1 gene in patients with cancers as well as second site mutations that alter the function of the Dicer protein expressed. Here, we present a review of mutations in the DICER1 gene, the respective protein sequence changes, and clinical manifestations of DICER1 syndrome. Directions for future research are discussed. Keywords: DICER1 syndrome; DICER1 germline mutations; miRNA; rare genetic disorder; cancer 1. Introduction DICER1 syndrome, or pleuropulmonary blastoma familial tumor susceptibility syndrome (ORPHA: 284343; OMIM: 601200), is a rare genetic disorder predisposing individual to the development of tumors, both benign and malignant [1–3].
    [Show full text]